8th Annual Anogenital and Oral Dermatology Course
24 – 25 May 2018
The Royal College of Physicians
11 St Andrew’s Place
London, NW1 4LE
Thursday 24 May 2018 09:30 – 17:00 (registration from 09:00)
Friday 25 May 2018 09:00 – 17:10 (registration from 08:30)
Overview of the programme
DAY ONE – Thursday 24 May 2018
- Oral disease
- Male genital disease
DAY TWO – Friday 25 May 2018
- Vulval Disease
Overall aims and objectives
This course provides participants with an overview of anogenital and oral dermatology, including diagnosis, treatment options, dealing with complications and co morbidities, and the latest research in the field. Throughout the programme clinical based studies will be used to highlight current treatments and to combine theory and clinical practice.
Who should attend?
This two-day annual course is aimed at all healthcare professionals (dermatology, gynaecology, GU medicine, oral medicine, GPs, and specialist nurses) who wish to learn more about the diagnosis and management of male and female anogenital and oral dermatological disorders. It will address the importance of multidisciplinary working in the care of these patients.
The course combines presentations, interactive lectures, case studies, examples of good practice and Q&A sessions. Twelve (12) CPD points have been applied for from the Royal College of Physicians.
Delegates will receive comprehensive course materials to take away.
Dr Fiona Lewis
Consultant Dermatologist, St John’s Institute of Dermatology, Guy’s and St Thomas’ and Heatherwood and Wexham Park Hospital
Dr Lewis has a developed a special interest in Vulval disease and completed her MD thesis on Lichen sclerosus. She now leads the Vulval clinics at St John’s Institute of Dermatology. She has published widely on many aspects of the subject and co-authors the textbook Ridley’s ‘The Vulva’. She teaches regularly both locally and internationally and was Secretary of the European College for the Study of Vulval Disease.
Dr Jane Setterfield
Reader/Honorary Consultant in Oral Dermatology, Department of Oral Medicine KCL DI, St John’s Institute of Dermatology, Guy’s and St Thomas‘
Dr Setterfield leads the Oral Dermatologsy Service at St John’s Institute. Dr Setterfield has developed a special interest in oral and mucocutaneous diseases. She has published widely on many aspects of mucocutaneous including mucous membrane pemphigoid, pemphigus and lichen planus She teaches regularly both locally and internationally and is a member of the European and British Societies for Oral Medicine.
Professor Chris Bunker
Consultant Dermatologist, University College London Hospitals
Professor Bunker studied medicine at Cambridge University and Westminster Medical School, and completed his general training in NHS hospitals in Derby, London and Oxford. He went on to specialise in dermatology at the Middlesex Hospital and at University College London Hospitals (UCLH) NHS Foundation Trust. He was appointed Consultant Dermatologist at UCLH in 2010. Previous to this, he had been a Consultant Physician in Dermatology at the Chelsea and Westminster, Charing Cross and Royal Marsden hospitals for almost 20 years. He is the Immediate Past President of the British Association of Dermatologists. His clinical and research interests include melanoma, male genital dermatoses and HIV dermatology.
Two day attendance
- Consultants/GP standard – £385
- Nurse and trainee standard – £265
One day attendance
- Consultants/GP standard – £215
- Nurse and trainee standard – £145
Looking for accommodation?
To help you to find special offers at nearby hotels, we’ve included a HotelMap™ which shows you the nearest accommodation options at competitive rates.
If you have any enquiries about this course, please contact the events team:
020 7185 6034
This course has been kindly supported by the companies listed below.
These companies have had no input or influence over the programme or content of the course.
DermaSilk is a range of Class I Medical Devices with published evidence base in sensitive skin conditions such as eczema, lichen sclerosus, RVVC and VLSC. It is made from hypoallergenic silk which is permanently protected with an antimicrobial to keep the briefs fresh and reduce bacterial and fungal colonisation on the fabric. A simple change of underwear can help decrease the external sources of irritation, manage excessive moisture production and decrease candida proliferation.
DermaSilk briefs are included in the 2014 European Dermatology Forum Guidelines for LS and the 2016 European Guidelines for the Management of Vulval Conditions. Studies demonstrated a reduction in pain, burning and irritation over just a 4 week period, with the most dramatic reduction after the first week. Importantly, better results were obtained by wearing them both day and night.
The results also showed:-
- 75% reported improvements in social/leisure activities
- 63% slept better at night
- 67% reported improvements in their sexual relationships
- 100% of patients noted that the briefs had helped their condition
Available to prescribe or recommend www.dermasilkintimo.co.uk
Tel: 01462 346100
Since 1963 Dermal has been at the forefront of innovative topical formulations, developing highly effective, cosmetically acceptable and clinically proven therapies for the management of various skin conditions, including eczema and psoriasis. Dermal understands that it is the performance of the formulation as a whole that makes the difference and can help improve patient adherence. We recognise the importance of careful maintenance of the skin barrier and our leading emollient ranges are specially formulated for use on sensitive and irritated skin.
The Doublebase range of gel emollients is highly moisturising and cosmetically acceptable; and the Dermol range of antimicrobial emollients can be particularly helpful to protect against secondary infection of compromised skin. To help patients effectively manage their skin conditions by avoiding irritant soaps and SLS, both of these ranges contain gentle soap substitutes to provide a complete emollient therapy routine.
The latest addition to the Dermal portfolio is a new product – Adex Gel. Adex Gel is a simple and different approach to the treatment of dry skin conditions prone to inflammation, e.g. eczema and psoriasis. To learn more visit www.AdexGel.com.
Recognising that education is key to empowering patients in the management of their skin conditions, we offer an extensive range of resources for healthcare professionals and patients. To hear our latest news and to find out how our emollient ranges can be helpful in managing dry skin conditions on sensitive areas please find us at our stand or visit www.Dermal.co.uk.
Kora Healthcare has launched Catephen, the first licensed herbal treatment in the UK. A Green tea extract Catephen 10% is the first herbal preparation for the cutaneous treatment of external genital and perinanal warts in immunocompetent patients from the age of 18 years. Kora Healthcare has launched Catephen, the first licensed herbal treatment in the UK. A Green tea extract Catephen 10% is the first herbal preparation for the cutaneous treatment of external genital and perinanal warts in immunocompetent patients from the age of 18 years.
- BASSH (2015) Guidelines for the Management of Anogenital warts
- European Guideline for the Management of Anogenital warts
- NICE Evidence Summary (2015) External genital and perinanal warts: green tea (Camellia sinensis) leaf extract 10% ointment
Kora Healthcare continues to build a dynamic presence by marketing leading prescription and consumer healthcare brands in the therapeutic areas of Clinical Nutrition, Sexual Health, Infectious Diseases and Point of Care Testing. Within its current portfolio, Kora Healthcare markets an assortment of leading brands including Prescription Only Medicines, Pharmacy Medicines, Medical Devices, Dietary Foods for Special Medical Purposes and Food Supplements.
Solutions with you in mind. At Almirall, we dedicate ourselves to finding real solutions for real needs. Our mission is to provide valuable medicines and medical devices to you and future generations. To do this, we complement our extensive research and development programme with a strategic partner network, while remaining firmly connected to all those whose lives we touch.
For more information about Almirall, visit almirall.com
Janssen collaborates with the world for the health of everyone in it.
From our headquarters in High Wycombe, Buckinghamshire, we focus on collaborating with patient organisations and the NHS to improve patients’ lives and follow in the footsteps of our founder, Dr Paul Janssen, who famously said “patients are waiting.”
Find more information at janssen.com/uk
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
To learn more about Lilly, please visit us at lilly.co.uk
Novartis transform patients’ lives by targeting progressive illnesses in the Specialty Dermatology and Rheumatology fields, where there are high unmet medical needs.
Find more information at www.novartis.co.uk
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare.
Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat.
Our Aim is to translate our research and experience into results that have a real life impact on patients’ lives.
Sanofi Genzyme and Regeneron are committed to providing resources to advance research in dermatology in areas of unmet medical needs among patients with poorly controlled moderate-to-severe atopic dermatitis.
Find more information at www.sanofi.co.uk
PCDS Summer Meeting
Wellcome Collection, London NW1 2BE
Thursday 28th June 2018
For more information click here to download the programme
24 June 2019